Published in Cancer on August 01, 2010
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. Eur J Hum Genet (2011) 2.64
Surrogate decision makers' interpretation of prognostic information: a mixed-methods study. Ann Intern Med (2012) 1.73
Unrealistic optimism and the ethics of phase I cancer research. J Med Ethics (2012) 1.55
Adolescent perspectives on phase I cancer research. Pediatr Blood Cancer (2012) 1.16
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol (2012) 1.11
Confronting Therapeutic Failure: A Conversation Guide. Oncologist (2015) 1.09
What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. J Virus Erad (2015) 0.96
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet (2013) 0.96
New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond) (2011) 0.94
Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study. Trials (2012) 0.94
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol (2014) 0.90
Clinical trial participation as part of end-of-life cancer care: associations with medical care and quality of life near death. J Pain Symptom Manage (2013) 0.90
"Is it really worth it to get tested?": primary care patients' impressions of predictive SNP testing for colon cancer. J Genet Couns (2012) 0.87
Modes of hoping: understanding hope and expectation in the context of a clinical trial of complementary and alternative medicine for chronic pain. Explore (NY) (2014) 0.87
Comparison of enrollees and decliners of Parkinson disease sham surgery trials. Mov Disord (2012) 0.87
"It is not guaranteed that you will benefit": True but misleading? Clin Trials (2015) 0.82
Conflicts among multinational ethical and scientific standards for clinical trials of therapeutic interventions. J Law Med Ethics (2012) 0.82
Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist (2013) 0.81
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All? Neurotherapeutics (2015) 0.81
Ways of Hoping: Navigating the Paradox of Hope and Despair in Chronic Pain. Cult Med Psychiatry (2016) 0.79
The role of therapeutic optimism in recruitment to a clinical trial in a peripartum setting: balancing hope and uncertainty. Trials (2016) 0.79
"Is a cure in my sight?" Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials. Genet Med (2013) 0.78
Phase 1 clinical trials in end-stage cancer: patient understanding of trial premises and motives for participation. Support Care Cancer (2013) 0.78
Negotiating decisions during informed consent for pediatric Phase I oncology trials. J Empir Res Hum Res Ethics (2012) 0.78
Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication. Death Stud (2015) 0.77
Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception? J Med Ethics (2014) 0.76
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. Public Health Genomics (2014) 0.75
A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer (2016) 0.75
Study partners perform essential tasks in dementia research and can experience burdens and benefits in this role. Dementia (London) (2016) 0.75
Clinical features of Parkinson's disease patients are associated with therapeutic misconception and willingness to participate in clinical trials. Trials (2017) 0.75
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Sample size in qualitative research. Res Nurs Health (1995) 7.10
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep (1987) 5.64
Designing a mixed methods study in primary care. Ann Fam Med (2004) 3.89
Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB (2003) 3.82
Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med (2002) 3.62
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Phase I cancer trials. A collusion of misunderstanding. Hastings Cent Rep (2000) 2.90
Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol (2006) 2.73
Battling breast cancer. [Review of: Lerner, BH. The breast cancer wars: hope, fear, and the pursuit of a cure in twentieth-century America. Oxford University Press, 2001]. Rev Am Hist (2002) 2.56
Ethics of phase 1 oncology studies: reexamining the arguments and data. JAMA (2003) 2.28
Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer (2005) 1.71
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study. Cancer (2007) 1.64
American oncology and the discourse on hope. Cult Med Psychiatry (1990) 1.63
Why patients continue to participate in clinical research. Arch Intern Med (2008) 1.62
Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol (2000) 1.47
Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. Theor Med Bioeth (2003) 1.46
The problem with optimism in clinical trials. IRB (2006) 1.38
Oncology and hope. J Clin Oncol (1995) 1.36
An approach to evaluating the therapeutic misconception. IRB (2009) 1.35
Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making (2008) 1.34
Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum (2000) 1.27
Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol (1984) 1.23
The discursive properties of "hope": a qualitative analysis of cancer patients' speech. Qual Health Res (2002) 1.22
A need to try everything: patient participation in phase I trials. J Adv Nurs (2001) 1.22
Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology (2008) 1.17
Trusting God and medicine: spirituality in advanced cancer patients volunteering for clinical trials of experimental agents. Psychooncology (2005) 1.01
Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncol Nurs Forum (1997) 1.00
Patient optimism and mastery-do they play a role in cancer patients' management of pain and fatigue? J Pain Symptom Manage (2008) 0.99
Hope and hoping in the talk of dying cancer patients. Soc Sci Med (2006) 0.98
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA (2005) 4.93
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol (2003) 3.31
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. J Gen Intern Med (2005) 2.25
Beliefs and attitudes of nurses and physicians about do not resuscitate orders and who should speak to patients and families about them. Crit Care Med (2008) 2.23
Differences in the patterns of health care system distrust between blacks and whites. J Gen Intern Med (2008) 2.20
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol (2002) 1.84
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Aff (Millwood) (2008) 1.74
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
Is failure to meet spiritual needs associated with cancer patients' perceptions of quality of care and their satisfaction with care? J Clin Oncol (2007) 1.60
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol (2003) 1.54
Development of a revised Health Care System Distrust scale. J Gen Intern Med (2008) 1.53
Institutional review boards' use and understanding of certificates of confidentiality. PLoS One (2012) 1.53
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Community hospital oversight of clinical investigators' financial relationships. IRB (2009) 1.51
Patient reactions to confidentiality, liability, and financial aspects of informed consent in cardiology research. Circ Cardiovasc Qual Outcomes (2010) 1.50
Validity of a simple ST-elevation acute myocardial infarction risk index: are randomized trial prognostic estimates generalizable to elderly patients? Circulation (2003) 1.50
Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol (2002) 1.49
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Performance of the Thrombolysis in Myocardial Infarction (TIMI) ST-elevation myocardial infarction risk score in a national cohort of elderly patients. Am Heart J (2005) 1.48
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
Using cognitive interviews to evaluate items for measuring sexual functioning across cancer populations: improvements and remaining challenges. Qual Life Res (2009) 1.46
Developing a simplified consent form for biobanking. PLoS One (2010) 1.45
Cancer patient preferences for quality and length of life. Cancer (2008) 1.43
Using central IRBs for multicenter clinical trials in the United States. PLoS One (2013) 1.43
Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research. Ann Emerg Med (2008) 1.42
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A (2003) 1.41
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res (2005) 1.39
Sexual functioning along the cancer continuum: focus group results from the Patient-Reported Outcomes Measurement Information System (PROMIS®). Psychooncology (2010) 1.39
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas (2008) 1.38
Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer (2005) 1.37
An evaluation of mobile health application tools. JMIR Mhealth Uhealth (2014) 1.37
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther (2007) 1.35
Trends in centralization of cancer surgery. Ann Surg Oncol (2010) 1.35
Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making (2008) 1.34
Simplifying informed consent for biorepositories: stakeholder perspectives. Genet Med (2010) 1.29
When patients lack capacity: the roles that patients with terminal diagnoses would choose for their physicians and loved ones in making medical decisions. J Pain Symptom Manage (2005) 1.29
Proteomic analyses of pancreatic cyst fluids. Pancreas (2009) 1.29
A randomized trial of generic versus tailored interventions to increase colorectal cancer screening among intermediate risk siblings. Ann Behav Med (2009) 1.26
Development of the NIH PROMIS ® Sexual Function and Satisfaction measures in patients with cancer. J Sex Med (2013) 1.25
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
How would terminally ill patients have others make decisions for them in the event of decisional incapacity? A longitudinal study. J Am Geriatr Soc (2007) 1.20
Decision making and quality of life in the treatment of cancer: a review. Support Care Cancer (2008) 1.19
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol (2003) 1.17
Patient experiences with communication about sex during and after treatment for cancer. Psychooncology (2011) 1.17
Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiol Biomarkers Prev (2007) 1.16
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol (2012) 1.16
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer (2007) 1.14
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.13
Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med (2006) 1.12
Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist (2010) 1.12
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol (2012) 1.11
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational model. Prev Med (2003) 1.10
Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature. Clin Trials (2013) 1.09
Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. PLoS One (2008) 1.09
Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. Cancer (2002) 1.08
Cost concerns of patients with cancer. J Oncol Pract (2013) 1.07
Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. Patient Educ Couns (2008) 1.05
Ongoing challenge of stage II colon cancer. J Clin Oncol (2011) 1.04
Circulating tumor cells: evolving evidence and future challenges. Oncologist (2009) 1.04
Targeting signal transduction pathways in colorectal cancer--more than skin deep. J Clin Oncol (2005) 1.04
Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care (2013) 1.04
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2007) 1.03
Comparison of conflict of interest policies and reported practices in academic medical centers in the United States. Account Res (2007) 1.03
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2002) 1.03
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res (2004) 1.02
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res (2002) 1.02
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer (2003) 1.01
Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.00
Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 1.00